Scientists found a molecular clue in their search for ways to wipe out one of the most devastating tropical diseases on earth. Known as river blindness, Onchocerciasis is a leading cause of vision loss, especially in the developing world. Yet the disease leaves behind a biomarker in the urine of patients that could easily identify those in need of treatment.
Ignyta will work with Leiden University Medical Center on new biomarker research involving patients with early synovitis and rheumatoid arthritis.
In the fall of 2011, CardioKinetix raised the first half of its $44 million Series E round. Now, the California company and 2012 Fierce 15 winner has nailed down the difference, a $23 million second tranche. Plans call for putting the money to work immediately in a variety of ways to advance the company's second-generation Parachute Ventricular Partitioning Device for heart failure.
West Pharmaceutical Services rolled out an adapter for standard needles that enables easier and more consistent delivery into a patient's skin at a very shallow angle.
The news on the biosimilar R&D front has been all bad in recent months--at least for the biggest players in the business. Merck, Teva and Samsung have all experienced severe setbacks, scrapping follow-on programs for some of the biggest biologic targets now on the market.
A new study showed a glimmer of hope for a troubled nicotine vaccine after a series of clinical trial setbacks, as investigators hold out hope for new weapons against smoking, a leading cause of deadly cancers, lethal lung disease and other fatal ailments. Yet evidence from the latest study could be too scant to win over some skeptics.
Researchers at Genzyme have found a way to deliver drugs that shut down the genes associated with the neuromuscular disease myotonic dystrophy type 1, a type of muscular dystrophy.
Jazz Pharmaceuticals has stepped up to grab the worldwide rights to a tweaked version of the narcolepsy drug Xyrem from Lexington, MA-based Concert Pharmaceuticals, a biotech which has been making a splash with its deuterium-modification approach for next-gen therapeutics.
GlaxoSmithKline encountered some stiff industry headwinds when it pledged to open up its data vault to outside investigators. But as of today it has a high-profile convert on its side. The biopharma giant Roche has agreed to follow in GSK's footsteps, saying that it will work with an independent group which will be charged with sorting out and approving requests for access to anonymized clinical trial data for all approved products. If regulators can't provide the data, says Roche, then the company will make it available.
The diabetes treatments Januvia and Byetta may double patients' risk of pancreatitis, a new study finds.